In a transformational period since its April 2015 IPO on AIM, Motif Bio plc has made significant progress in advancing its late clinical-stage antibiotic programme. Motif is now pursuing a NASDAQ listing in preparation for the drug’s future US launch. We believe that a US listing could help bridge the significant valuation gap between Motif and its US peers. In the wake of a major antibiotic resistance crisis, the treatment’s sales could run into billions of US dollars per year. ....
